TruSight Cystic Fibrosis (日本未発売)

FDA-regulated, CE-marked in vitro diagnostic (IVD) next-generation sequencing assay conveniently providing two cystic fibrosis tests in one product.

この製品は出荷できる国が制限されています。 出荷の可否を確認するには、 出荷する国を選択してください

MiSeqDx Reagent Kit v3, Micro provides a flexible, cost-saving option for running a smaller batch size of 24-36 samples. This product is currently validated for exclusive use with the TruSight Cystic Fibrosis 139-Variant Assay. Available in select geographies.  

Overview

TruSight Cystic Fibrosis is an FDA-regulated in vitro diagnostic (IVD) NGS solution that consolidates two cystic fibrosis assays into a single workflow.  

  • Combines an ancestrally diverse variant panel with full CFTR sequencing  

  • Provides efficient library prep and highly flexible throughput

  • Generates a highly accurate and easily interpreted report 

TruSight Cystic Fibrosis 139-Variant Assay

Accurately detects 139 clinically relevant CFTR variants defined in the CFTR2 database as of August 2013.1   

  • Improves detection of CF-causing variants from 72 to ~91% sensitivity2 

  • Reduces additional testing with reliable results

  • Provides comprehensive detection across diverse demographics3  

TruSight Cystic Fibrosis Clinical Sequencing Assay 

Captures all variants in the protein coding regions and intron/exon boundaries for a complete view of the CFTR gene.

  • Delivers deep coverage (> 3000×) for detection accuracy with a Positive Agreement (PA) of 99.66% (includes polyTG/polyT variants) 

  • Removes demographic bias inherent in existing genotyping panels3 

  • Automatically detects polyTG/polyT variants 

  • Uncovers rare mutations not accounted for in standard tests 

Specifications

Required Products

Showing 1 - 1 / 1

FAQs

Showing 1 - 4 / 4

NovaSeq Xシリーズのご購入

進化したケミストリー、光学、インフォマティクスを融合させ、卓越したシーケンシング速度とデータ品質、優れたスループットとスケーラビリティをお届けします。

MiSeq Reagent Kit v3

以前のバージョンと比較して、クラスター密度とリード長が増加し、シーケンスのクオリティスコアが改善、最適化された試薬キット。

TruSight Oncology 500

すべての主要なバリアントクラスとFFPE組織からの遺伝子シグネチャ(TMB、MSIおよびHRD)をカバーする大規模な腫瘍横断型パネルでCGPを実現。

Illumina DNA Prep

幅広いシーケンス アプリケーションに対応するライブラリーを調製するための、高速で統合されたワークフロー。

References:

1. Clinical and Functional Translation of CFTR. www.cftr2.org. Accessed August 2013. 

2. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nature Genetics. 2013;45(10):1160-1167. doi:10.1038/ng.2745

3. Hughes EE, Stevens CF, Saavedra-Matiz CA, et al. Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Human Mutation. 2016;37(2):201-208. doi:10.1002/humu.22927

4. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004;6(5):387-391. doi:10.1097/01.gim.0000139506.11694.7c

5. Committee on Genetics. The American College of Obstetricians and Gynecologists Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gyncol. 2011;486:1-4. doi:https://pubmed.ncbi.nlm.nih.gov/21422883/

Speak with a specialist

Reach out for information about our products and services, or get answers to questions about our technology.